1 Placental transfer dynamics and durability of maternal COVID-19 vaccine-induced

- 2 antibodies in infants
- 3
- 4 Authors: Paola A. Lopez^{a*}, Nadège Nziza^{b*}, Tina Chen^b, Lydia L. Shook^{c,d,e}, Madeleine D.
- 5 Burns^f, Stepan Demidkin^d, Olyvia Jasset^d, Babatunde Akinwunmi^g, Lael M. Yonker^{e,f}, Kathryn J.
- 6 Gray^{e,g}, Michal A. Elovitz^h, Douglas A. Lauffenburger^{a**}, Boris D. Julg^{b,e**}, Andrea G.
- 7 Edlow^{c,d,e**}
- 8

9 Affiliations:

- 10 ^aDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA,
- 11 USA
- 12 ^bRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
- 13 CMassachusetts General Hospital, Department of Obstetrics and Gynecology, Division of
- 14 Maternal-Fetal Medicine, Boston, MA, USA
- 15 ^dMassachusetts General Hospital, Vincent Center for Reproductive Biology, Boston, MA, USA
- 16 ^eHarvard Medical School, Boston, MA, USA
- 17 ^fMassachusetts General Hospital for Children, Department of Pediatric, Boston, MA, USA
- 18 ^gBrigham and Women's Hospital, Department of Obstetrics and Gynecology, Division of
- 19 Maternal-Fetal Medicine, Boston, MA, USA
- 20 ^hWomen's Biomedical Research Institute, Icahn School of Medicine at Mount Sinai
- 21 * Contributed equally as co-first authors
- 22 ** Contributed equally as co-last authors
- 23
- 24 Correspondence/Lead Contact:
- 25 Andrea G. Edlow
- 26 Vincent Center for Reproductive Biology
- 27 Massachusetts General Hospital
- 28 55 Fruit Street, Thier Research Building, 9th floor
- 29 Boston, MA 02114
- 30 Email: aedlow@mgh.harvard.edu
- 31
- 32 Keywords: COVID-19, pregnancy, placental transfer, antibody transfer, infant, vaccines, fetal sex,
- 33 Fc-receptor, immunoglobins
- 34
- 35
- 36
- 37
- 38
- 38
- 39
- 40

41

42 SUMMARY

43

Completion of a COVID-19 vaccination series during pregnancy effectively reduces COVID-19 44 hospitalization among infants less than 6 months of age. Elucidating the dynamics of transplacental 45 transfer of maternal vaccine-induced antibodies, and their persistence in infants at 2, 6, 9 and 12 46 months, has implications for new vaccine development and timing of vaccine administration in 47 pregnancy to optimize protection of the mother-infant dyad. We evaluated anti-COVID antibody 48 IgG subclass, Fc-receptor binding profile, and activity against wild-type Spike and RBD, and five 49 variants of concern (VOCs) in 153 serum samples from 100 unique infants. Maternal IgG1 and 50 IgG3 responses persisted in 2- and 6-month infants to a greater extent than the other IgG 51 subclasses, with highest persistence of antibodies that bind placental neonatal Fc-receptor as well 52 as FcyR3A. Timing of maternal vaccination and fetal sex were drivers of antibody persistence in 53 infants. Lowest persistence at 2 and 6 months was observed against the Omicron RBD-specific 54 55 region. Maternal vaccine timing, placental Fc-receptor binding capabilities, antibody subclass, fetal sex, and VOC all impact the persistence of maternal vaccine-induced antibodies in infants up 56 to 12 months. 57

58

60 INTRODUCTION

The U.S. Centers for Disease Control and Prevention (CDC) recommends that everyone over the 61 age of 6 months receive both doses of the mRNA COVID-19 vaccine (BNT162b2 and mRNA-62 1273)^{1,2}. Large population-based studies have shown that a two-dose series of the mRNA COVID 63 64 vaccine provides moderate protection against symptomatic infection in children³, as well as in the development of severe COVID-19-associated outcomes⁴. However, there is a lack of knowledge 65 regarding how maternal vaccine timing, placental Fc-receptor binding and fetal characteristics 66 drive transplacental antibody transfer and persistence of antibodies in infants over the first year of 67 68 life.

69

70 While infants under the age of 6 months remain ineligible to receive the COVID-19 vaccine, they 71 are one of the populations at highest risk for severe COVID-19 in the setting of SARS-CoV-2 infection. Infants younger than 6 months not only have higher COVID-19 hospitalization rates 72 73 compared to other pediatric groups, but also are at higher risk for acquiring life-threatening complications from COVID-19, including acute respiratory failure ^{5,6}. Maternal immunization is 74 a key strategy to protect infants younger than 6 months from infectious diseases through passive 75 transplacental antibody transfer ⁷. Additionally, maternal immunization shapes infant immune 76 development by priming the cellular immune response⁸. Although the level of antibody necessary 77 78 to achieve infant protection against severe COVID-19 remains unknown, one study showed that the completion of the COVID-19 vaccination during pregnancy is correlated with reduced 79 COVID-19 hospitalization rates in infants younger than 6 months of age, with greater protection 80 for infants conferred when the mother received the COVID-19 mRNA vaccine after 20 weeks 81 82 gestational age ^{9–11}. More granular information on how timing of maternal vaccination influences infant antibody levels over the first year of life was previously not available. 83

84

Recent studies examining COVID-19 vaccination during pregnancy have demonstrated the 85 transplacental antibody transfer of anti-Spike immunoglobin (Ig) G antibodies ^{12–16}. While there 86 are limited data on the persistence of maternal anti-Spike IgG antibodies in infants ^{16,17}, no study 87 has performed comprehensive profiling of maternal COVID-19 vaccine-induced antibodies that 88 persist in infants through 12 months of age, including all IgG subclasses, Fc receptor (FcR) binding 89 90 profiles, and against both SARS-CoV-2 wild-type and variants of concern (VOCs) including B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), P.1 (Gamma), and B.1.1.529 (Omicron) 91 variants. FcR binding is a critical consideration, as the Fc region of the antibodies plays an 92 important role in protection against infection and the resolution of SARS-CoV-2 infection ^{18,19} by 93 inducing the antiviral activity of the innate immune system ^{20,21}. The Fc region of antibodies also 94 plays a critical role in the transfer of antibodies across the placenta ^{22,23}, and a more granular 95 understanding of antibodies that persist in infants after maternal COVID vaccination may have 96 broader implications for understanding optimal vaccine timing and features of vaccine-induced 97 98 antibodies that maximize neonatal and infant protection. Such an understanding may be relevant 99 to new vaccines with specific indications for pregnant individuals, including the RSV vaccine and

100 others still in development. In this study, we performed unbiased systems serology to evaluate the

- 101 levels and FcR binding profile of SARS-CoV-2-specific antibodies transferred from mother to
- 102 infants, as well as their persistence in infants up to 12 months of age. Our analyses reveal
- 103 differences in antibody profiles of infants whose mothers were vaccinated at different stages of
- 104 gestation. This work further highlights the importance of understanding the timing of vaccination
- in pregnancy to provide optimal protection to susceptible infants during their first critical monthsof life.
- 107

108 **RESULTS**

Maternal COVID-19 vaccine-induced antibodies are detected in infants up to 12 months of age

- 111 To comprehensively profile COVID-19 vaccine-induced antibodies in infants up to 6 months of
- age, we evaluated 153 plasma/serum samples from a prospectively-collected cohort of 100
- unique infants, including N=55 infants at two months, N=80 infants at 6 months, N=14 infants at
- 114 9 months, and N=4 infants at 12 months. Maternal (N=84) and cord (N=76) blood was available
- for a subset of the infants. During the course of the study, none of the included infants tested
- positive for COVID-19 (see Methods and Supplemental Figure 1). The mothers in this study all
- received both doses of the first generation (2020-2021) mRNA vaccinations (mRNA-1273 or
- 118 BTN162b) or one dose of the Ad26.CoV2.S vaccine during pregnancy, and were not infected
- 119 with SARS-CoV-2 prior to vaccination or during pregnancy. Table 1 details relevant clinical
- 120 characteristics of mothers and infants in the study.
- 121
- 122 We first plotted the Spike- and RBD-specific wild-type (WT) IgG antibody titer of mother-cord dyads, and 2-month-old and 6-month-old infants (Figure 1A). Expanding upon previous reports 123 examining primarily total IgG against Spike ^{14,24–26}, our results show cord samples are similar to 124 maternal with respect to anti-Spike and anti-RBD IgG subclasses and IgG FcR binding responses. 125 126 We observed that anti-Spike WT IgG1 was the most persistent antibody at 6 months of age, with 70% (56/80) of 6-month-old infants having detectable anti-Spike WT IgG1, while only 11% (9/80) 127 had detectable IgG3 antibody levels, 2/80 with detectable anti-Spike IgG2, and no infants showing 128 detectable levels of IgG4. 129
- 130

We also observed similar persistence trends between Spike- and RBD-specific antibodies. 73% (58/80) of 6-month-old infants had detectable anti-RBD WT IgG1, 23% (18/80) had detectable IgG3, 9% (7/80) had detectable IgG2, and 3/80 infants had detectable anti-RBD WT IgG4. These findings are overall consistent with previous reports of a transfer hierarchy of subclass-specific IgG transfer through the placenta from the mother to cord, with IgG1 > IgG3 > IgG4 > IgG2²⁷⁻²⁹.

- 136
- 137 Furthermore, we observed detectable Spike-specific and RBD-specific FcR-binding IgG levels in
- 138 infants through 6 months of age (Figure 1B). Interestingly, 47/55 2-month infants demonstrated
- 139 detectable antibody binding profiles against Spike-specific and 55/55 against RBD-specific

140 neonatal Fc receptor (FcRn), with similarly high detection of antibodies binding canonical Fcreceptors FcyR2A and FcyR3B at 2 months of age (Figure 1B). However, greater differences in 141 142 the persistence of the FcR-binding against Spike versus RBD in infants begin to emerge at 6 143 months of age. We observed only 29% (23/80) of infants had detectable antibodies binding Spike-144 specific FcRn, 9% (7/80) binding FcyR2A, 10% (8/80) binding FcyR2B, 53% (42/80) binding FcyR3A, and 18% (14/80) binding to FcyR3B. RBD-specific Fc-receptor binding was more 145 persistent than that against Spike, with 88% (70/80) of infants having detectable RBD-specific 146 antibodies binding FcRn, 74% (59/80) binding FcyR2A, 24% (19/80) binding FcyR2B, 69% 147 148 (55/80) binding to FcyR3A, and 33% (26/80) binding to FcyR3B. Combined, these data demonstrate higher persistence of WT RBD-specific Fc-receptor binding IgGs compared to WT 149 150 Spike at 6 months, with highest persistence of antibodies binding FcRn.

151

152 We also analyzed the levels of the same Spike- and RBD-specific WT antibodies in infants 9 months (N=12) and 12 months (N=4) of age (Supplemental Figure 2). We observed 10/12 infants 153 at 9 months, and 2/4 infants at 12 months had detectable Spike-specific IgG1 levels. Similar 154 155 persistence was observed for IgG1 against RBD (8/14 at 9 months, 1/4 at 12 months of age). There 156 was negligible persistence of other IgG subclasses at 9 and 12 months of age. We also observed detectable FcR binding levels of RBD-specific antibodies only, with 13/14 9-month infants 157 demonstrating detectable binding to FcRn, and 2/14 and 3/14 demonstrating detectable RBD-158 159 specific binding to FcyR3AV and FcyR2AR, respectively.

160

Of note, 12 infants whose mothers received the Ad26.CoV2.S vaccine were enrolled in the study 161 and systems serology was performed on their samples, including 8 at 2 months, 3 at 6 months and 162 163 1 at 9 months. Of these 12, 75% (9/12) mothers were vaccinated at > 20 weeks' gestation. These infants were included in all analyses except those pertaining to maternal timing of vaccine dose 1 164 and dose 2, which is only relevant to the mRNA vaccines (Supplemental Figures 3-5 Figures 3-4). 165 Understanding antibody persistence in infants whose mothers received Ad26.CoV2.S may be 166 167 relevant for future adenovirus-based vaccine engineering or viral-based therapeutics; we therefore 168 report here that 6 / 9 infants had detectable IgG Spike-WT antibodies at 2 months, 1/3 infants at 6 169 months, and none at 9 months of age.

170

Persistence of maternal COVID-19 vaccine-induced antibodies at 6 months of age differs by Variants of Concern

- 173
- 174 Next, we examined the cross-reactivity of the maternal COVID-19 vaccine induced antibodies and

antibody FcR binding profile against wild-type SARS-CoV-2 Spike and RBD, as well as Spike

- and RBD VOCs in cord and infant samples (Figure 2A). Of note, the vaccines were administered
- to mothers between 12/18/20 and 6/22/21, and thus represent the first generation BNT162b2 and
- mRNA-1273 vaccines. To evaluate the persistence of the maternal vaccine-induced antibodies in
- 179 infants against the VOCs, we compared the percent of infants in each group with detectable IgG

subclasses and FcR binding profiles against Spike-specific and RBD-specific regions of the VOCs

- 181 (Figure 2A).
- 182

The first-generation COVID-19 mRNA vaccines generated antibodies cross-specific against most 183 184 VOCs that persisted to 6 months, with highest persistence of antibodies cross-binding to Delta and to Gamma and lowest to Omicron. For all IgG subclasses and Fc receptor profiles apart from IgG2 185 and IgG4, we observed detectable levels of antibodies and FcR binding against either the RBD- or 186 Spike-specific antigen of all VOCs except Omicron in infants up to 6 months of age (Figure 2A). 187 These findings are consistent with previous work from our group, demonstrating that the Spike-188 189 specific vaccine-induced antibodies were able to robustly bind to other VOCS, with lower affinity 190 observed for the RBD-specific region of the VOCs³⁰. As seen for WT Spike and RBD (Figure 1A), IgG2 and IgG4 subclasses overall had low persistence, including against the different VOCs. 191 192 While there was relatively high persistence of IgG1 at 6 months against Spike-specific Omicron 193 (70% of infants showing detectable IgG1 antibodies), very few (N=9/80) 6-month infants had 194 detectable IgG3 against Spike-specific Omicron, and only 14/80 6-month infants had detectable 195 Spike-specific Omicron antibodies with Fc-receptor binding capabilities, with highest persistence 196 of antibodies binding FcyR3A (8/80). While IgG1 against Omicron RBD persisted at 6 months in 54 % (43/80) of infants, a sharp decrease in the persistence of IgG3 against RBD-specific Omicron 197 198 was observed, with only 5/55 infants demonstrating detectable levels of this antibody even at 2 199 months (Figure 2B). We also saw strikingly low persistence of RBD-specific Omicron FcR 200 binding in 2- and 6-month infants, with only FcRn-binding antibodies persisting to any significant extent. The reduced ability of vaccine-generated antibodies to bind the highly-mutated³¹ RBD 201 202 region of the Omicron Spike protein relative to other VOCs has been demonstrated previously³². 203 The data presented here suggest that RBD-specific anti-Omicron antibodies also may engage non-204 canonical placental Fc-receptors to a lesser extent than antibodies against other VOCs, given their 205 significantly reduced persistence in 2- and 6-month-old infants.

206

207 The timing of maternal vaccination influences antibody levels in 2-month-old infants

Previous studies have demonstrated that timing of initiation of COVID-19 vaccination in 208 209 pregnancy influenced the levels of maternal vaccine-induced antibodies at delivery and 210 transplacental transfer to the umbilical cord^{14,16,24,33,34}. Knowledge is lacking, however, regarding how the timing of not only the first, but also the second dose of the mRNA vaccine in pregnancy, 211 212 impacts maternal antibody levels and persistence of antibody in infants. Thus, we wanted to 213 examine specifically how the timing of both first and second mRNA vaccine dose impacted the 214 profile of passively transferred maternal antibodies in infants. The 2-month cohort was selected for this subanalysis, given the higher and more uniformly persistent levels of all antibody features 215 216 in this group, relative to the 6-month-old infant cohort.

217

First, we grouped the 2-month infant cohort into five groups, based on when the pregnant individual received dose 1 and dose 2 of the primary mRNA COVID-19 vaccination series (Figure

220 3A). For this analysis, we excluded infants whose mother received the Ad26.CoV.2 vaccine, as 221 only a single dose of this vaccine was administered (N=8 2-month infants). Timepoints of < 20weeks, 20-28 weeks and > 28 weeks were chosen as cut points for analysis, given previous work 222 223 from the CDC demonstrating that maternal vaccination after 20 weeks' gestation was more 224 effective in preventing COVID-19-associated infant hospitalizations in the first 6 months of life, relative to when maternal vaccination was completed prior to 20 weeks^{9,10}. The 20-28 week and 225 >28 week window were selected to gain increased trimester-specific granularity on optimal timing 226 of maternal vaccine administration. 227

228

229 Levels of Spike-specific IgG subclasses and Fc-receptor binding antibodies in 2-month-old infants by maternal vaccine timing are plotted in Figure 3B. These analyses demonstrated that for most 230 subclasses and Fc receptor binding features, infants whose mother received at least one dose of 231 mRNA vaccine after 28 weeks (Groups 4 and 5, maroon and rose groups) had the highest levels 232 233 of maternal COVID-19 vaccine-induced antibodies. Interestingly, the lowest level of IgG1 and 234 IgG2 subclasses and Fc receptor binding features was seen in infants whose mothers received both doses of the mRNA vaccine in the 20-28 week window. Given the prior data demonstrating 235 enhanced protection against COVID-19-associated hospitalization when the vaccine series was 236 completed after 20 weeks' gestation^{9,10}, we hypothesized we would observe the lowest antibody 237 238 titers in infants whose mothers started and/or completed the entire vaccine series prior to 20 weeks. Instead, we observed that receiving both doses of the mRNA vaccine in the mid-to-late second 239 240 trimester (Group 3, yellow) was associated with the lowest levels of anti-spike IgG1 and IgG2 in infants, which was consistent with prior work in a separate cohort, suggesting less robust maternal 241 242 antibody responses in second trimester vaccination relative to first and third¹⁴. These less robust 20-28 week responses were hypothesized to be secondary to the known relative maternal immune 243 quiescence of the second trimester, which occurs at least in part to facilitate rapid fetal growth³⁵. 244

245

246 However, the finding that the lowest antibody levels were seen in infants whose mothers started and finished the vaccine in the 20-28 week window should be interpreted with an important caveat: 247 Group 3 included 9 males and only 1 female infant, whereas other groups in this analysis were 248 comprised by nearly equal numbers of males and females. Univariate analyses revealed that male 249 250 infant sex was associated with significantly reduced levels of Spike-specific IgG2 antibodies at 2 months of age relative to female infants (Supplemental Figure 3A). We also observed reduced 251 levels of Spike-Specific IgG1 antibodies in male infants compared to female infants, although this 252 finding did not achieve statistical significance (Supplemental Figure 3A). Uniform Manifold 253 Approximation and Projection Analysis (UMAP) also revealed antibody and Fc-receptor variation 254 255 by timing of maternal vaccination and infant sex (Group 3, Supplemental Figure 3B). It is therefore 256 possible that the lower titers noted in infants after late second trimester maternal vaccination are a 257 function of either maternal vaccine timing, male infant sex, or both.

259 Finally, we observed that infants whose mother received at least one dose of mRNA vaccine prior to 20 weeks' gestation had the highest levels of IgG4. Previous work demonstrated that IgG4 260 antibodies after COVID-19 vaccination were less inflammatory and had more muted effector 261 functions (antibody-dependent phagocytosis and complement deposition) than other subclasses, 262 and IgG4 levels rose with longer interval from 2nd mRNA vaccination³⁶. Thus, the elevated IgG4 263 levels in infants whose mothers were vaccinated at < 20 weeks may be present due to increased 264 passage of time and increased opportunity for antibody class switching in the mother, and these 265 antibodies may have more muted effector functions and therefore may be less desirable to pass to 266 infants than other subclasses of IgG. Consistent with this concept, we observed the highest levels 267 of IgG3, the subclass most associated with an effective early anti-viral response³⁷ in infants whose 268 269 mothers received the first vaccine dose after 20 weeks' gestation.

270

271 Given the observed differences in infant antibody levels by timing of maternal vaccination, we 272 next sought out to determine the combination of features that best separated infants based on timing 273 of vaccination using partial least squares discriminant analysis (PLSDA), followed by least absolute shrinkage and selection operator (LASSO) feature regularization to prevent overfitting 274 275 (Figure 3C). The LASSO-selected features that are important (based on Variable Importance in 276 Projection (VIP) analyses) in building a model to distinguish groups based on maternal vaccine 277 timing are highlighted in Figure 3C, and include not only the Spike-specific WT antibody levels 278 and FcR binding profiles, but also some RBD-specific and VOC-specific features. Other features 279 used in building the PLSDA model, as well as the model validation results, are depicted in Supplemental Figure 4A and 4B. Among the top features that distinguish the groups, three (anti-280 281 RBD Beta IgG3, anti-Spike gamma IgG3, and anti-Spike WT IgG2) were enriched in either Group 4 or Group 5 (at least one vaccine dose administered > 28 weeks), and 2 features (anti-Spike beta 282 IgG4 and anti-RBD delta IgG4) were enriched in Group 1 or 2 (at least one vaccine dose 283 administered < 20 weeks, Figure 3C and Supplemental Figure 4A). Similar to levels of IgG 284 285 subclasses, numerous FcR binding features were enriched in Group 4 or Groups 4 and 5, primarily relative to Group 3 (fully vaccinated 20-28 week window). 286 287

Given that LASSO selects a minimal set of features to prevent overfitting of the data, we generated 288 289 a correlation heatmap to determine additional features that correlate with the top features used in the PLSDA model (Supplemental Figure 4C). IgG3 and IgG4 features, regardless of antigen target, 290 were correlated with other IgG3 and IgG4 antibodies, respectively (Spearman correlation rho > 291 0.75). Spike- and RBD-specific IgG3 and Spike-specific IgG2 both were positively correlated with 292 FcR binding levels. Overall, these analyses demonstrated that the timing of not only the 1st but 293 294 also the 2nd dose of maternal COVID-19 vaccination influence antibody subclass levels in 2-295 month-old infants.

296

To evaluate the impact of maternal vaccine timing on antibody features in 6-month infants, we sought to determine a set of features that best separate 6-month infants based on maternal

299 vaccination timing, as was done with the 2-month infant cohort, using LASSO feature regularization in conjunction with PLSDA classification (Supplemental Figures 5A-C). Similar to 300 the results in 2-month infants, the LASSO-selected features show an enrichment of antibody levels 301 in 6-month infants whose mother was vaccinated > 28 weeks (Supplemental Figures 5B and 5C). 302 303 Although the univariate plots of these features did not demonstrate statistically significant differences, these plots demonstrate that infants whose mothers received the vaccine > 28 weeks 304 305 had elevated antibody and Fc-receptor binding levels compared to those vaccinated <20 or 20-28 306 weeks (Supplemental Figure 5D).

307

Evaluating the persistence of maternal-vaccine-induced antibodies in 6-month infants by timing of the maternal COVID-19 vaccine series in early versus later 3rd trimester: implications for RSV vaccination in pregnancy

311

312 Recently, the CDC's Advisory Committee on Immunization Practices recommended the bivalent 313 recombinant respiratory syncytial virus prefusion F protein (RSV preF) vaccine for seasonal use in pregnant individuals at 32-36 weeks' gestation, to prevent RSV lower respiratory tract disease 314 in infants³⁸. In a large randomized controlled trial of over 7300 pregnant individuals, RSV 315 vaccination from 24-36 weeks was associated with protection efficacy of 69.4% against severe 316 lower respiratory tract disease in infants at 6 months of age³⁹. However, RSVpreF vaccination was 317 ultimately approved in pregnant individuals in the narrower window of 32-36 weeks' gestation. 318 319 As this narrower and later window was not explicitly studied in the trial, and given our findings that timing of maternal vaccination administration had significant impact on antibody persistence 320 321 in infants, we sought to examine antibody persistence in infants at 6 months with maternal administration of the COVID-19 vaccines at 28-32 weeks versus 32-36 weeks' gestation in our 322 sample. While this is a different vaccine platform with a two-dose rather than one dose regimen, 323 given the lack of data on antibody persistence in infants when maternal vaccines are administered 324 325 at 32+ weeks of gestation, these data can add significantly to existing knowledge.

326

First we evaluated antibody features in 6-month-old infants as a function of timing of maternal 327 vaccination in pregnancy using polar plots (Figure 4A). Because of their low persistence in the 6-328 329 month infant cohort (Figure 1A), we excluded IgG2 and IgG4 from these analyses (overall more than 70% of the samples for IgG2 and IgG4 fell below the limit of detection threshold). Comparing 330 331 the mean percentile ranks of antibody subclasses and Fc-receptor binding features persistent in 6-332 month-old infants by maternal vaccine timing in pregnancy, it was clear that maternal vaccination 333 at > 28 weeks was associated with the most robust persistence of antibodies in 6-month-old infants 334 (relative to < 20 weeks or 20-28 weeks). These results were thus consistent with the prior results 335 for 2-month-old infants (Figure 3).

336

To parse more specifically how timing of maternal vaccination within the 3rd trimester influenced persistence of infant antibody titers at 6 months, we then evaluated levels of IgG subclasses and

Fc-receptor binding antibody levels in 6-month infants as a function of maternal vaccination from 339 28-32 weeks (Figure 4B), versus maternal vaccination from 32-36 weeks (Figure 4C). We found 340 that the majority of antibody features, including IgG subclasses and Fc-receptor binding, were 341 significantly positively correlated with gestational age at maternal vaccine administration across 342 343 the 28-32 weeks' gestation period, particularly IgG1 against RBD and Spike WT and VOCs, as 344 well as FcyR2AR-, FcyR3AV- and FcyR3B-binding antibodies (Figures 4B, 4D). In contrast, many 345 of the same features decreased steadily as a function of time across the vaccine window when maternal vaccination was initiated from 32-36 weeks (Figures 4C, 4D). In summary, these 346 347 analyses demonstrate a significant positive correlation between infant antibody levels at 6 months 348 and gestational age at vaccination across the 28-32 week gestational age window. However, this 349 relationship reverses across the 32-36 week window, with a significant negative correlation between 6-month infant antibody levels and gestational age at maternal vaccination These limited 350 351 data suggest that the efficiency of transplacental transfer of maternal antibodies and durability in infants through 6 months of age may be reduced across the 32-36 week gestational age window. 352

353

354 **DISCUSSION**

355 Maternal vaccination against COVID-19 has been shown to effectively reduce COVID-19 related hospitalization rates in infants younger than 6 months ^{9,10}, through the transplacental transfer of 356 maternal COVID-19 vaccine induced antibodies ^{16,17}. Here, using systems serology, we profiled 357 maternal antibodies in 100 infants up to 12 months of age in unprecedented detail. These 358 359 experiments quantified not only total IgG level, but IgG subclass and FcR binding profile of antibodies against wild type Spike and RBD epitopes of SARS-CoV-2, as well as a wide range of 360 361 variants of concern including Omicron. Although the COVID-19 pandemic is ongoing and protecting both mothers and vulnerable infants under 6 months of age who cannot yet be 362 363 vaccinated against COVID-19 remains critical, our findings have relevance far beyond COVID-19. Our findings that antigen specificity (e.g., Spike versus RBD), IgG subclass (e.g. IgG1 and 364 IgG3), and canonical (FcRn) versus non-canonical (Fcy) placental receptor binding work in 365 concert to drive persistence of antibodies in infants through 6 months of age may have implications 366 367 for both future vaccine development and timing of administration in pregnancy. Our findings that both timing of maternal vaccination and fetal sex were significantly associated with persistence of 368 maternally-transferred antibody in infants may be used to guide both pregnancy vaccination 369 strategies, and our understanding of infant protection. Finally, our granular examination of the 370 impact of maternal vaccine timing within the mid to late 3rd trimester demonstrates enhanced 371 antibody persistence in 6-month infants when vaccine occurs across the 28-32 week window, yet 372 373 reduced persistence across the 32-36 week window, with potential immediate relevance for maternal RSV vaccination strategies. Thus, the detailed antibody map presented here provides the 374 375 basis for a more mechanistic understanding of maternal antibody generation, transplacental 376 transfer, and persistence of antibodies across the mother-infant dyad.

While limited data are available regarding the persistence of maternal COVID-19 vaccine-induced 378 379 antibodies in infants^{16,17} this represents the largest study examining infant antibody persistence, with comprehensive infant follow up at 2, 6, 9 and even 12 months of age, albeit with more limited 380 numbers profiled after 6 months. In addition, these represent the only available data regarding the 381 persistence of IgG subclasses and FcR binding profiles in infants through 12 months of age. Our 382 observation of IgG1 and IgG3 having the highest persistence in 6 month infants is consistent with 383 the known transfer hierarchy of subclass-specific IgG transfer through the placenta from the 384 mother to cord, with $IgG1 > IgG3 > IgG4 > IgG2^{27-29}$. Subclass-specific IgG transfer hierarchy is 385 mediated not only by the relative abundance of each subclass, but also FcR expression levels and 386 387 Fc-FcR interaction affinity²⁸. As an example, IgG3, one of the most persistent antibodies in 6month infants, has high binding affinity to placental FcyR3A⁴⁰. In addition to facilitating IgG3 388 transfer across the placenta, the finding that the most persistent FcR binding profiles at 6 months 389 390 were for antibodies binding FcyR3A suggests preferential transfer of natural killer (NK) cellactivating antibodies^{23,41} to arm neonates with the most effective immunity from birth, as NK cells 391 play a crucial role in neonatal first-line innate immune defenses⁴². 392

393

394 With respect to timing of maternal vaccination in pregnancy, prior epidemiologic studies demonstrated that maternal COVID-19 vaccination after 20 weeks' gestation conferred the greatest 395 infant protection against COVID-19-associated hospitalizations in the first 6 months of life^{9,10}. 396 397 These studies did not examine antibody levels in infants, nor did they examine the impact of vaccination timing within the second half of pregnancy on infant protection. While there are 398 limited data available on antibody levels in infants after maternal COVID-19 vaccination^{16,17}, these 399 studies have not examined how timing of vaccination across a range of trimesters or within 400 trimester impacts infant antibody levels. There are also no data on relative persistence of different 401 402 IgG subclasses, nor on FcR binding, or activity against VOCs in infants within the first year of life. Our finding of the highest levels of IgG1-3 and FcR binding in infants whose mother was 403 vaccinated with at least one dose of the mRNA vaccine after 28 weeks of gestation, and 404 significantly lower IgG levels and FcR binding in infants born to mothers fully vaccinated in the 405 406 20-28 week window, builds upon our prior work demonstrating enhanced IgG levels, FcR binding and functions when mothers are vaccinated in 3rd relative to 2nd trimester^{14,43}. The finding that 407 IgG4 was highest in infants born to mothers vaccinated prior to 20 weeks likely can be at least 408 partially explained by antibody class switching and a time effect, with < 20 week vaccinees having 409 410 more time for class-switching to IgG4 and transfer of Ig4 across the placenta. IgG4 may be a less advantageous antibody subclass for newborns and early infants with immature immune systems, 411 given that IgG4 responses are T-cell dependent^{14,43} and have reduced effector functions (e.g., 412 antibody-dependent cellular phagocytosis and complement deposition)^{44,45}. 413

414

415 Also relevant to considerations of timing of maternal vaccination is our focused subanalysis 416 examining durability of placentally-transferred antibodies in 6-month-old infants after maternal

417 vaccination in mid- to late-third trimester. This question is timely given the recent recommendation

418 by the FDA and CDC/ACIP to restrict maternal RSV vaccination to the 32-36 week window of 419 pregnancy^{46–48}. Our data suggest that most effective transfer occurs in the context of maternal 420 vaccination in the early third trimester (28-32 weeks), with progressively less efficacious placental transfer (reflected in lower levels of IgG and Fc-receptor binding) as vaccination occurs from 32-421 422 36 weeks. These limited data point to maternal RSV vaccination in the earlier part of the 32-36 week window potentially being more optimal to maximize infant protection through 6 months of 423 age. These data should be interpreted with caution as the RSV vaccine is a different platform 424 (recombinant protein) and a one- rather than two-shot regimen, with likely different transfer 425 kinetics. However, given the current dearth of evidence to guide vaccine timing within the 426 427 recommended window, we offer these analyses while we await further prospective data from 428 pregnant RSV vaccine recipients and their infants.

429

430 With respect to the impact of infant sex on infant antibody persistence at 2 and 6 months of age after maternal vaccination, our finding that male infants had reduced persistence of antibodies at 431 2 and 6 months relative to females resonates with prior published data. Prior work by our group 432 found that pregnant individuals carrying male infants had lower maternal levels of COVID-433 specific antibodies and reduced FcR binding antibody levels, compared to individuals carrying 434 female infants after natural COVID infection⁴⁹. Sex-specific anti-COVID antibody glycan profiles 435 436 and sex-specific patterns of placental Fc-receptor expression that may be less favorable for transplacental antibody transfer to male infants were also previously reported⁴⁹. Maternal immune 437 response, specific antibody properties such as glycan profiles, and placental FcR expression all are 438 influenced by fetal sex, making this a critical area for further research. 439

440

Lastly, we examined whether maternal vaccination with the first-generation COVID-19 vaccines 441 induced antibodies against other VOCs, persistent in 2 and 6 month old infants, finding the most 442 consistent cross-immunity was induced for the gamma and delta variants, but with persistent levels 443 444 of antibodies and Fc receptor engagement against all VOCs in infants up to 6 months of age with the exception of Omicron. Persistence of Omicron RBD-specific IgG3 was negligible, with nearly 445 446 no detectable levels of this antibody in even 2-month infants. Similarly, there was strikingly low Omicron RBD-specific Fcy-receptor binding in 2- and 6-month infants in comparison to other 447 VOCs or even to Omicron Spike-specific Fcy-receptor binding. This could be due to the 448 disproportionately high mutation burden in the RBD region of the Omicron Spike protein³¹. The 449 450 extent to which these potential deficits in activity against Omicron could be overcome by infant or childhood vaccination with updated Omicron-specific COVID-19 vaccines is an important 451 question. Additionally, it is likely that maternal vaccination with an updated COVID-19 booster 452 against Omicron could augment transfer of Omicron Spike- and RBD-specific antibodies to 453 infants, and this is a critical area of ongoing investigation⁵⁰. Finally, these data highlight the 454 importance of comprehensive antibody profiling to better understand the complexity of immunity 455 transferred to the infant by maternal vaccination; such data clearly have implications for vaccine 456 design and/or implementation strategies, particularly against pathogens with high mutation rates. 457

- 458
- 459 These results demonstrate that COVID-19 vaccination during pregnancy provides not only a robust antibody response in the mother, but antibodies detectable in infants through > 6 months of age. 460 A fine-grained understanding of antibody subclasses and Fc-receptor binding profiles that persist 461 462 in infants through 1 year of life is critical not only for understanding protection afforded infants by maternal COVID-19 vaccination, but for the development of rational vaccines and data-driven 463 maternal vaccination strategies. Our findings related to the critical impact of vaccine timing across 464 gestation and of infant sex on antibody durability at 2 and 6 months of age demonstrate the 465 importance of ongoing investigations of these unique aspects of maternal-fetal immunity that 466 467 should inform vaccine development, and can drive strategies to optimize maternal and neonatal immunity against a wide array of pathogens. 468
- 469

470 ACKNOWLEDGEMENTS

471 Funding sources: Merck Sharp & Dohme Corp Investigator-Initiated Studies grant (MISP 61299,

- 472 to A.G.E.); NIH/NIAID 1U19AI167899-01 to D.A.L., A.G.E., M.A.E., B.D.J.; NIH/NHLBI
- 473 5K08HL143183 to L.M.Y.
- 474

475 AUTHOR CONTRIBUTIONS

476 A.G.E., P.A.L., B.D.J., N.N., D.A.L developed the concept, designed the experiments, and

analyzed and interpreted the data. A.G.E., D.A.L., M.A.E., and B.D.J. obtained funding. N.N,

and T.C. performed experiments. P.A.L and D.A.L performed the statistical modeling. P.A.L.

and A.G.E. wrote the main paper. S.B., R.M.D., S.D., M.K.K., and C.D.P. collected and

480 prepared samples. L.L.S., M.D.B., O.J., B.A., L.M.Y., K.J.G., A.G.E. recruited and enrolled

481 participants. O.J., M.D.B., B.A., K.J.G., L.M.Y., and A.G.E. assisted with clinical data

- 482 collection. M.A.E. gave conceptual advice and edited the manuscript. All authors approved of
- the final manuscript.
- 484

485 DECLARATION OF INTERESTS

This work was supported in part by a research grant from the Investigator-Initiated Studies
Program of Merck Sharp & Dohme Corp (MISP 61299). The opinions expressed in this paper are

those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. K.J.G.

- 489 has consulted for Illumina, BillionToOne, and Aetion outside the scope of the submitted work.
- 490 A.G.E. and M.A.E. serve as medical advisors for Mirvie. M.A.E has equity in Mirvie outside the
- 491 submitted work. B.D.J.'s immediate family member, Galit Alter, is co-founder of Seromyx
- 492 Systems, Inc., and has a patent on Systems Serology Platform pending.
- 493
- 494

495 **TABLE 1**

496

	Overall unique infant (N= 100)	2 month- old infants (N = 55)	6 month- old infants (N = 80)	9 month- old infants (N = 14)	12 month- old infants (N = 4)
Vaccine Platform, N (%) mRNA-1274 BNT162b.2 Ad.26.COV2.S	31 (31) 59 (59) 10 (10)	17 (31) 30 (55) 8 (15)	28 (35) 48 (60) 4 (5)	8 (57) 5 (36) 1 (7)	1 (25) 3 (75) 0 (0)
Infant Sex, N (%) Female	49 (49)	24 (44)	41 (51)	6 (43)	3 (75)
Gestational age at 1 st mRNA vaccine in maternal series, N (%) < 20 weeks 20 – 28 weeks > 28 weeks	26 (29) 29 (32) 35 (39)	23 (49) 16 (34) 8 (17)	20 (26) 26 (34) 30 (40)	1 (7) 7 (54) 5 (36)	0 (0) 0 (0) 4 (100)
Gestational age at 2 nd mRNA vaccine in maternal series, N (%) < 20 weeks 20 – 28 weeks > 28 weeks	15 (17) 27 (30) 48 (53)	12 (25) 21 (45) 14 (30)	13 (17) 22 (29) 41 (54)	0 (0) 3 (23) 10 (77)	0 (0) 0 (0) 4 (100)
Gestational age at Ad26.COV2.S Vaccine, N (%) < 20 weeks	3 (30)	3 (37.5)	0 (0)	0 (0)	0 (0)
20 – 28 weeks > 28 weeks	2 (20) 5 (50)	2 (25) 3 (37.5)	1 (25) 3 (75)	0 (0) 1 (100)	0 (0) 0 (0)

497

498 Table 1: Clinical characteristics of included infants

All included infants ($N_p = 100$) reflect the first maternal COVID-19 vaccination series. Some infants' samples were collected at multiple time points, thus there are a total of 153 infant samples from 100 unique infants. All infants were born to mothers who were fully vaccinated in pregnancy as defined at the time (received both doses of the original COVID-19 mRNA vaccine series, or a single dose of the Ad26.COV2.S vaccine). None of the included infants had symptoms of COVID-19 nor did they ever test positive for SARS-CoV-2.

506	STAR Methods
507	
508	RESOURCE AVAILABILITY
509	
510	Lead Contact
511	Requests for information should be directed to the lead contact, Andrea G. Edlow
512	(aedlow@mgh.harvard.edu)
513	
514	Material Availability
515	This study did not generate new unique reagents.
516	
517	Data and Code Availability
518	The dataset generated during this study is available upon reasonable request. Code used for the
519	analyses can be found at Mendeley Data: http://dx.doi.org/10.17632/35zy6p92f6.1
520	
521	EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
522	
523	Study Population
524	The study included N=108 unique infants born to mothers who received their initial COVID-19
525	vaccine series in pregnancy (dates of maternal vaccination Dec 18, 2020-June 22, 2021).
526	Mothers enrolled their infants in this study conducted from July 23, 2021 to July 1, 2022.
527	Ultimately samples collected from pregnant individuals infected with SARS-CoV-2 before
528	vaccination or babies known to be infected with SARS-CoV-2 prior to sample collection were
529	excluded (Supplemental Figure 1). Matched maternal and umbilical cord serum samples were
530	collected at birth for a subset of mothers co-enrolled in a complementary pregnancy cohort
531	(MGB IRB # 2020P003538). Infant capillary serum samples were collected via microneedle
532	device (TAP [®] II blood collection device, YourBio Health, Medford, MA) at 2 months, 6 months,
533	9 months and 12 months after birth for infants of vaccinated mothers. All infants were singletons
534	except for 2 pairs of twins. All included pregnant participants signed informed consent for
535	sample collection, and birthing parents signed consent for their infants (MGB IRB #s
536	2020P003538 and 2020P000955).
537	
538	METHOD DETAILS
539	
540	Antigens
541	Spike and RBD proteins of SARS-CoV-2 D614G or variants of concern, along with S1 and S2were
542	obtained from Sino Biological. These antigens were expressed in mammalian HEK293 cells. To
543	biotinylate these antigens, NHS-Sulfo-LC-LC kits were used following the manufacturer's
544	instructions (ThermoFisher Scientific).
545	

546 Multiplexed Luminex assay

547 Antigen-specific antibody levels and Fcy receptor binding were measured using a custom multiplexed Luminex assay, as previously described⁵¹. To couple the antigens to magnetic 548 carboxylated fluorescent Luminex beads (Luminex Corporation), carbodiimide-NHS ester 549 coupling was performed, with one bead region assigned to each antigen. The beads were first 550 551 activated in an activation buffer, which consisted of 100 mM monobasic sodium phosphate (pH 6.2), 50 mg/ml N-hydroxysulfosuccinimide (Sulfo-NHS; Pierce) resuspended in H₂0, and 1-ethyl-552 3-[3-dimethlyaminopropyl]carbodiimide-HCl (EDC; Pierce) resuspended in the activation buffer. 553 Following a 30-minute incubation at room temperature (RT), the activated beads were washed in 554 coupling buffer (50 mM morpholineethanesulfonic acid, MES; pH 5.0) and then incubated with 555 556 antigens for 2 hours at RT. Subsequently, the beads were blocked during a 30-minute incubation 557 at RT in phosphate-buffered saline (PBS)-TBN (containing 0.1% bovine serum albumin [BSA], 0.02% Tween 20, and 0.05% azide [pH 7.4]). Lastly, PBS-Tween (0.05% Tween 20) was used to 558 559 wash the beads coupled with the proteins, then the beads were stored in PBS with 0.05% sodium 560 azide at 4°C.

561

562 Antigen-specific immunoglobulin quantification

Antigen-coupled beads were incubated with different sera dilutions (between 1:50 and 1:100, 563 depending on the secondary reagent) at 4°C for 18 hours of shaking. After the incubation, the 564 beads were washed three times with PBS-Tween (0.05% Tween 20) and mixed to phycoerythrin 565 (PE)-conjugated mouse anti-human antibodies (IgG, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgM) 566 567 from Southern Biotech at a concentration of 1.3 µg/ml. Following an additional 1-hour incubation at RT with shaking, the beads underwent another three washes with PBS-Tween (0.05% Tween 568 569 20) and were then resuspended in sheath fluid (Luminex Corporation). To ensure accuracy, each serum sample was tested in duplicate. The levels of PE median fluorescence intensity (MFI) were 570 571 measured using the iQue screener plus (Intellicyt) analyzer.

572

573 Antigen-specific Fcy-receptor binding

- 574 To investigate the relative binding levels of antibodies to individual Fcy-receptors (FcyRs), Avi-
- tagged FcγR2AR (used to measure FcγR2A), FcyR2B (used to measure FcγR2B), FcγR3AV
- 576 (used to measure $Fc\gamma R3B$), and $Fc\gamma R3B$ were obtained from Duke Human Vaccine Institute⁵¹.
- 577 Biotinylation of these receptors was carried out using a BirA biotin-protein ligase (BirA500;
- 578 Avidity), and any excess biotin was removed using Zeba spin desalting columns (7K MWCO;
- 579 Thermo Fisher Scientific). Serum samples were diluted at a ratio of 1:500 and mixed with
- 580 antigen-coupled beads to form immune complexes. Following an 18-hour incubation at 4°C, the
- beads were washed three times with PBS-Tween (0.05% Tween 20). Streptavidin-R-
- 582 phycoerythrin (ProZyme) was then added to each biotinylated FcyR at a 4:1 molar ratio and
- allowed to incubate for 20 minutes at RT. Fluorescent labeled FcyRs (at a concentration of 1
- $\mu g/ml \text{ in } 0.1\% \text{ BSA-PBS}$) were subsequently added to the immune complexes, followed by an
- incubation of 1 hour at RT. Lastly, three washes with PBS-Tween (0.05% Tween 20) were done,
- then beads were resuspended in sheath fluid (Luminex Corporation) for analysis. The median PE

587 intensity was measured using the iQue screener plus (Intellicyt) system, and all samples were

- 588 tested in duplicate.
- 589

590 QUANTIFICATION AND STATISTICAL ANALYSIS

Analyses were divided between mothers vaccinated at < 20 weeks' gestation, versus 20-28 weeks 591 (window fully in the 2nd trimester) versus 28 weeks to delivery (3rd trimester) to reflect the known 592 increased protection against severe infant COVID-19 disease conferred by maternal vaccination 593 after 20 weeks' gestation (e.g. < 20 weeks, > 20 weeks)^{9,10}, and to further subset vaccination after 594 20 weeks' gestation into biological windows that coincide with the trimesters of pregnancy. All 595 596 statistical analyses and figure generation were performed using R (version 4.1.0). For Luminex 597 samples, all features were subtracted by phosphate-buffered saline (PBS) control values and were log₁₀-transformed. As in previous studies¹⁷, detectable Luminex-derived features were defined as 598 599 any value greater than the sum of the mean of the SARS-CoV-2 unvaccinated negative control 600 adult samples (collected before the pandemic) and one standard deviation of those samples.

601

For univariate analyses of differences between maternal, cord, and infant samples, and as well as
2-month-old infant groups that vary between vaccination timing, significance was determined by
Kruskal-Wallis followed by posthoc Benjamini-Hochberg adjustment. For analysis of the transfer
between maternal and cord dyads, significance was calculated by a Wilcoxon signed-rank test
followed by Benjamini-Hochberg.

607

Multivariate analyses of the systems serology data were performed in R (version 4.2.1). All log10 608 609 data were then centered and scaled. Luminex-derived features for which 70% of values fell below one standard deviation above the mean of SARS-CoV-2 unvaccinated negative control samples 610 were pruned. Uniform Manifold Approximation and Projection (UMAP), unsupervised 611 dimensionality reduction technique⁵², was performed to evaluate the effect of maternal vaccination 612 timing and fetal sex. Prior to UMAP analysis, the first 20 principal components (PCs) that explain 613 614 95% of the data were determined using principal component analysis (PCA)⁵³. These PCs were then mapped used to reduce the high-dimensional serological data into a two-dimensional space 615 with fine tuned parameters (n.neighbor = 30, min.dist =0.2). UMAP was performed using the R 616 617 package 'Seurat'.

618

For Partial Least Squares Discriminant Analysis (PLSDA) classification models, Least absolute
shrinkage and selection operator (LASSO) feature selection⁵⁴ was performed to extract the most
significant features in distinguishing our groups. LASSO feature selection was implemented in
the function select_lasso in the systemseRology package (version 1.0) and was performed 100
times, and only features that were chosen repeatedly were further analyzed in downstream
analyses. PLSDA was performed using the LASSO-selected features. To evaluate model

- 625 robustness, the permuted control models were first built by randomly shuffling the labels 100
- times. These control models were then cross-validated 10 times to determine the accuracy of our

- 627 model. Robustness was then calculated as the effect size of the actual and control distributions
- and defined as the exact p-values of the tail probabilities of the actual distributions within the
- 629 control distributions.

631 **REFERENCES**

- 633 1. CDC (2022). CDC recommends COVID-19 vaccines for young children (US Department of
 634 Health and Human Services, CDC).
- 635 2. CDC (2023). Interim Clinical Considerations for Use of COVID-19 Vaccines in the United
 636 States (US Department of Health and Human Services, CDC).
- 637 3. Powell, A.A., Kirsebom, F., Stowe, J., McOwat, K., Saliba, V., Ramsay, M.E., Lopez-Bernal,
 638 J., Andrews, N., and Ladhani, S.N. (2022). Effectiveness of BNT162b2 against COVID-19
 639 in adolescents. Lancet Infect. Dis. 22, 581–583. 10.1016/S1473-3099(22)00177-3.
- 4. Klein, N.P., Stockwell, M.S., Demarco, M., Gaglani, M., Kharbanda, A.B., Irving, S.A., Rao,
 S., Grannis, S.J., Dascomb, K., Murthy, K., et al. (2022). Effectiveness of COVID-19 PfizerBioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency
 Department and Urgent Care Encounters and Hospitalizations Among
- 644 Nonimmunocompromised Children and Adolescents Aged 5–17 Years VISION Network,
- 645 10 States, April 2021–January 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 352–358.
- 646 10.15585/mmwr.mm7109e3.
- 5. Hamid, S., Woodworth, K., Pham, H., Milucky, J., Chai, S.J., Kawasaki, B., Yousey-Hindes,
 K., Anderson, E.J., Henderson, J., Lynfield, R., et al. (2022). COVID-19–Associated
 Hospitalizations Among U.S. Infants Aged <6 Months COVID-NET, 13 States, June
 2021–August 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 1442–1448.
 10.15585/mmwr.mm7145a3.
- 6. Hobbs, C.V., Woodworth, K., Young, C.C., Jackson, A.M., Newhams, M.M., Dapul, H.,
 Maamari, M., Hall, M.W., Maddux, A.B., Singh, A.R., et al. (2022). Frequency,
 Characteristics and Complications of COVID-19 in Hospitalized Infants. Pediatr. Infect. Dis.
 J. 41, e81–e86. 10.1097/INF.0000000003435.
- 656 7. Marchant, A., Sadarangani, M., Garand, M., Dauby, N., Verhasselt, V., Pereira, L., Bjornson,
 657 G., Jones, C.E., Halperin, S.A., Edwards, K.M., et al. (2017). Maternal immunisation:
 658 collaborating with mother nature. Lancet Infect. Dis. *17*, e197–e208. 10.1016/S1473659 3099(17)30229-3.
- 8. Marchant, A., and Kollmann, T.R. (2015). Understanding the Ontogeny of the Immune
 System to Promote Immune-Mediated Health for Life. Front. Immunol. *6*.
 10.3389/fimmu.2015.00077.
- 9. Halasa, N.B., Olson, S.M., Staat, M.A., Newhams, M.M., Price, A.M., Boom, J.A., Sahni,
 L.C., Cameron, M.A., Pannaraj, P.S., Bline, K.E., et al. (2022). Effectiveness of Maternal
 Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–
 Associated Hospitalization in Infants Aged <6 Months 17 States, July 2021–January
 2022. MMWR Morb. Mortal. Wkly. Rep. *71*, 264–270. 10.15585/mmwr.mm7107e3.
- 10. Halasa, N.B., Olson, S.M., Staat, M.A., Newhams, M.M., Price, A.M., Pannaraj, P.S., Boom,
 J.A., Sahni, L.C., Chiotos, K., Cameron, M.A., et al. (2022). Maternal Vaccination and Risk

- of Hospitalization for Covid-19 among Infants. N. Engl. J. Med. *387*, 109–119.
 10.1056/NEJMoa2204399.
- I1. Zerbo, O., Ray, G.T., Fireman, B., Layefsky, E., Goddard, K., Lewis, E., Ross, P., Omer, S.,
 Greenberg, M., and Klein, N.P. (2023). Maternal SARS-CoV-2 vaccination and infant
 protection against SARS-CoV-2 during the first six months of life. Nat. Commun. *14*, 894.
 10.1038/s41467-023-36547-4.
- 12. Trostle, M.E., Aguero-Rosenfeld, M.E., Roman, A.S., and Lighter, J.L. (2021). High
 antibody levels in cord blood from pregnant women vaccinated against COVID-19. Am. J.
 Obstet. Gynecol. MFM *3*, 100481. 10.1016/j.ajogmf.2021.100481.
- 13. Nir, O., Schwartz, A., Toussia-Cohen, S., Leibovitch, L., Strauss, T., Asraf, K., Doolman, R.,
 Sharabi, S., Cohen, C., Lustig, Y., et al. (2022). Maternal-neonatal transfer of SARS-CoV-2
 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger
 RNA vaccine during pregnancy. Am. J. Obstet. Gynecol. MFM *4*, 100492.
 10.1016/j.ajogmf.2021.100492.
- 14. Atyeo, C.G., Shook, L.L., Brigida, S., De Guzman, R.M., Demidkin, S., Muir, C.,
 Akinwunmi, B., Baez, A.M., Sheehan, M.L., McSweeney, E., et al. (2022). Maternal
 immune response and placental antibody transfer after COVID-19 vaccination across
 trimester and platforms. Nat. Commun. *13*, 3571. 10.1038/s41467-022-31169-8.
- 15. Atyeo, C., DeRiso, E.A., Davis, C., Bordt, E.A., De Guzman, R.M., Shook, L.L., Yonker,
 L.M., Fasano, A., Akinwunmi, B., Lauffenburger, D.A., et al. (2021). COVID-19 mRNA
 vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and
 nonpregnant women. Sci. Transl. Med. *13*, eabi8631. 10.1126/scitranslmed.abi8631.
- 692 16. Cassidy, A.G., Li, L., Golan, Y., Gay, C., Lin, C.Y., Jigmeddagva, U., Chidboy, M.A., Ilala,
 693 M., Buarpung, S., Gonzalez, V.J., et al. (2023). Assessment of Adverse Reactions, Antibody
 694 Patterns, and 12-month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA
 695 Vaccination in Pregnancy. JAMA Netw. Open *6*, e2323405.
 696 10.1001/jamanetworkopen.2023.23405.
- 17. Shook, L.L., Atyeo, C.G., Yonker, L.M., Fasano, A., Gray, K.J., Alter, G., and Edlow, A.G.
 (2022). Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19
 Vaccination or Natural Infection. JAMA 327, 1087. 10.1001/jama.2022.1206.
- 700 18. Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M.D., Burke, J., Yu, J.,
 701 Feldman, J., Hauser, B.M., et al. (2020). Compromised Humoral Functional Evolution
 702 Tracks with SARS-CoV-2 Mortality. Cell *183*, 1508-1519.e12. 10.1016/j.cell.2020.10.052.
- 19. Wang, C., Li, Y., Kaplonek, P., Gentili, M., Fischinger, S., Bowman, K.A., Sade-Feldman,
 M., Kays, K.R., Regan, J., Flynn, J.P., et al. (2022). The Kinetics of SARS-CoV-2 Antibody
 Development Is Associated with Clearance of RNAemia. mBio *13*, e01577-22.
 10.1128/mbio.01577-22.

- 20. Mackin, S.R., Desai, P., Whitener, B.M., Karl, C.E., Liu, M., Baric, R.S., Edwards, D.K.,
 Chicz, T.M., McNamara, R.P., Alter, G., et al. (2023). Fc-γR-dependent antibody effector
 functions are required for vaccine-mediated protection against antigen-shifted variants of
 SARS-CoV-2. Nat. Microbiol. *8*, 569–580. 10.1038/s41564-023-01359-1.
- 711 21. Bruhns, P., and Jönsson, F. (2015). Mouse and human FcR effector functions. Immunol.
 712 Rev. 268, 25–51. 10.1111/imr.12350.
- Atyeo, C., Pullen, K.M., Bordt, E.A., Fischinger, S., Burke, J., Michell, A., Slein, M.D.,
 Loos, C., Shook, L.L., Boatin, A.A., et al. (2021). Compromised SARS-CoV-2-specific
 placental antibody transfer. Cell *184*, 628-642.e10. 10.1016/j.cell.2020.12.027.
- 23. Jennewein, M.F., Goldfarb, I., Dolatshahi, S., Cosgrove, C., Noelette, F.J., Krykbaeva, M.,
 Das, J., Sarkar, A., Gorman, M.J., Fischinger, S., et al. (2019). Fc Glycan-Mediated
 Regulation of Placental Antibody Transfer. Cell *178*, 202-215.e14.
 10.1016/j.cell.2019.05.044.
- 24. Mithal, L.B., Otero, S., Shanes, E.D., Goldstein, J.A., and Miller, E.S. (2021). Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am. J. Obstet. Gynecol. 225, 192–194. 10.1016/j.ajog.2021.03.035.
- Murphy, E.A., Guzman-Cardozo, C., Sukhu, A.C., Parks, D.J., Prabhu, M., Mohammed, I.,
 Jurkiewicz, M., Ketas, T.J., Singh, S., Canis, M., et al. (2023). SARS-CoV-2 vaccination,
 booster, and infection in pregnant population enhances passive immunity in neonates. Nat.
 Commun. *14*, 4598. 10.1038/s41467-023-39989-y.
- Prabhu, M., Murphy, E.A., Sukhu, A.C., Yee, J., Singh, S., Eng, D., Zhao, Z., Riley, L.E.,
 and Yang, Y.J. (2021). Antibody Response to Coronavirus Disease 2019 (COVID-19)
 Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord
 Blood. Obstet. Gynecol. *138*, 278–280. 10.1097/AOG.00000000004438.
- 731 27. Malek, A., Sager, R., Kuhn, P., Nicolaides, K.H., and Schneider, H. (1996). Evolution of
 732 Maternofetal Transport of Immunoglobulins During Human Pregnancy. Am. J. Reprod.
 733 Immunol. *36*, 248–255. 10.1111/j.1600-0897.1996.tb00172.x.
- Palmeira, P., Quinello, C., Silveira-Lessa, A.L., Zago, C.A., and Carneiro-Sampaio, M.
 (2012). IgG Placental Transfer in Healthy and Pathological Pregnancies. Clin. Dev.
 Immunol. 2012, 1–13. 10.1155/2012/985646.
- 29. Clements, T., Rice, T.F., Vamvakas, G., Barnett, S., Barnes, M., Donaldson, B., Jones, C.E.,
 Kampmann, B., and Holder, B. (2020). Update on Transplacental Transfer of IgG
 Subclasses: Impact of Maternal and Fetal Factors. Front. Immunol. *11*, 1920.
 10.3389/fimmu.2020.01920.
- 30. Bartsch, Y.C. (2022). Preserved recognition of Omicron spike following COVID-19
 messenger RNA vaccination in pregnancy. Am. J. Obstet. Gynecol. 227, 493.e1-493.e7.

31. Ou, J., Lan, W., Wu, X., Zhao, T., Duan, B., Yang, P., Ren, Y., Quan, L., Zhao, W., Seto, D.,
et al. (2022). Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies
multiple inter-variant recombination events. Signal Transduct. Target. Ther. 7, 138.
10.1038/s41392-022-00992-2.

- 32. Bartsch, Y.C., St. Denis, K.J., Kaplonek, P., Kang, J., Lam, E.C., Burns, M.D., Farkas, E.J.,
 Davis, J.P., Boribong, B.P., Edlow, A.G., et al. (2022). SARS-CoV-2 mRNA vaccination
 elicits robust antibody responses in children. Sci. Transl. Med. *14*, eabn9237.
 10.1126/scitranslmed.abn9237.
- 33. Yang, Y.J., Murphy, E.A., Singh, S., Sukhu, A.C., Wolfe, I., Adurty, S., Eng, D., Yee, J.,
 Mohammed, I., Zhao, Z., et al. (2022). Association of Gestational Age at Coronavirus
 Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome
 Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and
 Umbilical Cord Antibody Levels at Delivery. Obstet. Gynecol. *139*.
- 34. Gray, K.J., Bordt, E.A., Atyeo, C., Deriso, E., Akinwunmi, B., Young, N., Baez, A.M.,
 Shook, L.L., Cvrk, D., James, K., et al. (2021). Coronavirus disease 2019 vaccine response
 in pregnant and lactating women: a cohort study. Am. J. Obstet. Gynecol. 225, 303.e1303.e17. 10.1016/j.ajog.2021.03.023.
- 35. Mor, G., and Cardenas, I. (2010). The Immune System in Pregnancy: A Unique Complexity.
 Am. J. Reprod. Immunol. *63*, 425–433. 10.1111/j.1600-0897.2010.00836.x.
- 36. Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil, M.,
 Beileke, S., Schäfer, S., Zhong, J., et al. (2023). Class switch toward noninflammatory,
 spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci.
 Immunol. *8*, eade2798. 10.1126/sciimmunol.ade2798.
- 37. Korobova, Z.R., Zueva, E.V., Arsentieva, N.A., Batsunov, O.K., Liubimova, N.E.,
 Khamitova, I.V., Kuznetsova, R.N., Rubinstein, A.A., Savin, T.V., Stanevich, O.V., et al.
 (2022). Changes in Anti-SARS-CoV-2 IgG Subclasses over Time and in Association with
 Disease Severity. Viruses *14*, 941. 10.3390/v14050941.
- 38. SMFM (2023). RSV Vaccination in Pregnancy (Society for Maternal Fetal Medicine).
- 39. Kampmann, B., Madhi, S.A., Munjal, I., Simões, E.A.F., Pahud, B.A., Llapur, C., Baker, J.,
 Pérez Marc, G., Radley, D., Shittu, E., et al. (2023). Bivalent Prefusion F Vaccine in
 Pregnancy to Prevent RSV Illness in Infants. N. Engl. J. Med. *388*, 1451–1464.
 10.1056/NEJMoa2216480.
- 40. Castro-Dopico, T., and Clatworthy, M.R. (2019). IgG and Fcγ Receptors in Intestinal Immunity and Inflammation. Front. Immunol. *10*, 805. 10.3389/fimmu.2019.00805.
- 41. Bournazos, S., Gupta, A., and Ravetch, J.V. (2020). The role of IgG Fc receptors in
 antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633–643. 10.1038/s41577-02000410-0.

- 780 42. Lee, Y.-C., and Lin, S.-J. (2013). Neonatal Natural Killer Cell Function: Relevance to 781 Antiviral Immune Defense. Clin. Dev. Immunol. 2013, 1-6. 10.1155/2013/427696. 782 43. Atyeo, C., Shook, L.L., Nziza, N., Deriso, E.A., Muir, C., Baez, A.M., Lima, R.S., 783 Demidkin, S., Brigida, S., De Guzman, R.M., et al. (2023). COVID-19 booster dose induces 784 robust antibody response in pregnant, lactating, and nonpregnant women. Am. J. Obstet. 785 Gynecol. 228, 68.e1-68.e12. 10.1016/j.ajog.2022.07.014. 786 44. Pillai, S. (2023). Is it bad, is it good, or is IgG4 just misunderstood? Sci. Immunol. 8, 787 eadg7327. 10.1126/sciimmunol.adg7327. 788 45. Uversky, V.N., Redwan, E.M., Makis, W., and Rubio-Casillas, A. (2023). IgG4 Antibodies 789 Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 790 Spike Protein. Vaccines 11, 991. 10.3390/vaccines11050991.
- 46. FDA (2023). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in
 Infants (Food and Drug Administration).

47. CDC (2023). CDC recommends new vaccine to help protect babies against severe respiratory
syncytial virus (RSV) illness after birth (US Department of Health and Human Services,
CDC).

48. ACOG (2023). ACOG Unequivocally Supports ACIP's Recommendation Approving Use of
Maternal RSV Vaccine in Pregnancy (American College of Obstetricians and
Gynecologists).

49. Bordt, E.A., Shook, L.L., Atyeo, C., Pullen, K.M., De Guzman, R.M., Meinsohn, M.-C.,
Chauvin, M., Fischinger, S., Yockey, L.J., James, K., et al. (2021). Maternal SARS-CoV-2
infection elicits sexually dimorphic placental immune responses. Sci. Transl. Med. *13*,
eabi7428. 10.1126/scitranslmed.abi7428.

- 50. Lipschuetz, M., Guedalia, J., Cohen, S.M., Sompolinsky, Y., Shefer, G., Melul, E., Ergaz-Shaltiel, Z., Goldman-Wohl, D., Yagel, S., Calderon-Margalit, R., et al. (2023). Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization. Nat. Med. 29, 1155–1163. 10.1038/s41591-023-02270-2.
- 51. Brown, E.P., Licht, A.F., Dugast, A.-S., Choi, I., Bailey-Kellogg, C., Alter, G., and
 Ackerman, M.E. (2012). High-throughput, multiplexed IgG subclassing of antigen-specific
 antibodies from clinical samples. J. Immunol. Methods *386*, 117–123.
 10.1016/j.jim.2012.09.007.
- 52. McInnes, L., Healy, J., and Melville, J. (2020). UMAP: Uniform Manifold Approximation
 and Projection for Dimension Reduction. Preprint at arXiv.
- 813 53. Wold, S., Esbensen, K., and Geladi, P. Principal Component Analysis.
- 54. Tibshirani, R. (1996). Regression Shrinkage and Selection Via the Lasso. J. R. Stat. Soc. Ser.
 B Methodol. 58, 267–288. 10.1111/j.2517-6161.1996.tb02080.x.



816 FIGURES AND LEGENDS

817 818

Figure 1: Maternal vaccine-induced SARS-CoV-2 antibodies persist in 2-month-old and 6month-old infants

- 821 Dot plots showing (A) Spike-specific WT (top) and RBD-specific WT antibody levels and (B)
- FcR profiles of maternal (M), cord (C), 2-month-old infants (2 m), and 6-month-old infants (6
- 823 m). Significance was determined by a Kruskal-Wallis test followed by Benjamini-Hochberg
- 824 procedure for multiple hypotheses correction. If statistically significant, a two-sided Mann-
- 825 Whitney U test was performed. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). The dashed
- 826 line represents the level of detection for each feature, defined as one standard deviation above the
- mean value for assay negative biological controls (SARS-CoV-2 negative, unvaccinatedsamples).
- 829





Figure 2: IgG subclasses and Fc-receptor binding capacity of antibodies against SARS-CoV2 variants of concern in umbilical cord blood, 2-month-old, and 6-month-old infants

(A) The heatmap shows the ratio of infants with detectable antibody titer or FcR binding levels
N=76 for cord (C), N=55 for 2-month-old infants (2 M), and N=80 for 6-month-old infants (6 M)
against the Spike or RBD region of wild-type (WT) strain and Variants of Concern (VOCs)
including Alpha, Beta, Delta, Gamma, and Omicron.

(B) Univariate plots showing RBD-specific Omicron antibody IgG levels (top) and FcR binding
 profiles in cord (C), 2-month-old infants (2 m), and 6-month-old infants (6 m).

- 840 Significance was determined by a Kruskal-Wallis test followed by Benjamini-Hochberg
- 841 procedure for multiple hypotheses correction. If statistically significant, a two-sided Mann-
- 842 Whitney U test was performed. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). The dashed
- 843 line represents the level of detection for each feature, defined as one standard deviation above the
- 844 mean value for assay negative biological controls (SARS-CoV-2 negative, unvaccinated845 samples).



846

Figure 3: Maternal vaccine timing drives IgG levels and Fc-receptor binding profiles in 2month-old infants.

849 Infants whose mothers were vaccinated in the late second and early third trimester (received at

- least one dose of mRNA vaccine after 28 weeks) had the highest levels of antibodies at 2 months.
 (A) Diagram showing the grouping strategy for 2-month-old infants based on the Dose 1 (D1) and
- Big and showing the grouping strategy for 2-month-old matrix based on the Dose 1 (D1) and Big Dose 2 (D2) COVID-19 vaccination. Group 1: N = 12, Group 2: N = 11, Group 3: N = 10, Group
- by $2 (D_2) COVID-19$ vaccination. Group 1: N = 12, Group 2: N = 11, Group 3: N = 10, Gro
- 853 4: N = 6, Group 5: N = 8.
- **(B)** Univariate plots showing Spike-specific WT antibody and Fc receptor (FcR) levels of each 2-
- 855 month-old infant group (as shown in in Figure 3A) Significance was determined by a Kruskal-856 Wallis test followed by Benjamini-Hochberg procedure for multiple hypotheses correction. If
- statistically significant, a two-sided Mann-Whitney U test was performed. (*p<0.05, ****p<0.0001). The middle line represents the median, whereas the other lines represent the first and third quartiles.
- 860 (C) (Top) A partial-least squares discriminant model (PLSDA) was built using LASSO feature
- 861 regularization and variable selection of the infant cohort group, resulting a reduced set of

features that were consistently in at least 80 of the 100 LASSO models. (Bottom) Variable

863 importance in projection (VIP) score of the selected features. The magnitude indicates the

864 importance of the features in driving the separation in the model. The color of the feature

865 corresponds to the group to which the feature was enriched.





- (A) The polar plots depict the mean percentile ranks of the antibody features within 6 month
- 871 infants whose moms were vaccinated with the first dose of the mRNA COVID-19 vaccine <20
- 872 weeks (N=20), 20-28 weeks (N=26), and > 28 weeks (N=30). Each wedge represents an
- antibody feature, and the size of the wedge depicts the mean percentile ranging from 0-1.

- (B) Linear regression models fits the relationship between gestation age of dose 1 (days) (those
- vaccinated between 28 32 weeks) and anti-RBD WT IgG1, anti-S1 FcγR2AR, and anti-RBD
- 876 gamma FcyR3B. The rho and p-values are reported in the plot
- 877 (C) Linear regression models fits the relationship between gestation age of dose 1 (days) (those
- vaccinated between 32 36 weeks) and anti-RBD WT IgG1, anti-S1 FcγR2AR, and anti-RBD
- gamma FcyR3B. The rho and p-values are reported in the plot.
- (D) The heatmap shows the Spearman correlation score for each feature against gestational age
- 881 (days) within infant samples whose mothers received the first dose of the mRNA COVID-19
- vaccine between 28 32 weeks or 32 36 weeks. The red boxes indicate samples with a positive
- 883 Spearman correlation, blue boxes indicate samples with a negative Spearman correlation. Within
- each group, gray boxes are features which were excluded from the analysis (if >70% of values
- fell below the threshold of detection, defined as less than one standard deviation above the mean
- 886 of SARS-CoV-2 negative, unvaccinated control samples).
- 887